Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.5.0.2
Commitments and Contingencies (Details) - AbbVie Biotherapeutics Corp [Member] - USD ($)
9 Months Ended
Jul. 24, 2012
Sep. 30, 2016
Phase 1 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones payments $ 750,000 $ 750,000
Phase 2 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones payments   750,000
Phase 3 Clinical Trial of a licensed product [Member]    
Summary of milestone payment    
Milestones payments   1,500,000
Biological License Application filing with U.S. FDA [Member]    
Summary of milestone payment    
Milestones payments   1,750,000
First commercial sale [Member]    
Summary of milestone payment    
Milestones payments   1,500,000
After first net sales [Member]    
Summary of milestone payment    
Milestones payments   $ 1,500,000